Pacira Pharmaceuticals (PCRX) Has Upside as EXPAREL Roll-Out Kicks into Gear - Wedbush
Tweet Send to a FriendGet Alerts PCRX Hot Sheet
Price: $29.55 +0.37%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 35 | New: 12
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 35 | New: 12
Trade PCRX Now!
Today Wedbush reiterated an Outperform rating and $18 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).
Analyst Richard Lau said “We believe $2.3MM in sales for the first quarter of launch along with positive launch metrics suggest a very promising roll-out of EXPAREL and expect the momentum to continue.”
As of August 3rd, Pacira stated that 428 customers have ordered EXPAREL which is up from 164 customers as of May 8th and that they are adding roughly 26 new customers per week, noted today’s report.
“49% of all accounts and 55% of hospital accounts have reordered with some accounts having ordered up to 15 times,” said Lau. “In our view, the reorder patterns suggest that initial physician experience has been positive and utilization will continue to grow as more hospitals gain access to EXPAREL”
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $14.94 yesterday, with a 52 week range of $6.51-$16.93.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst Richard Lau said “We believe $2.3MM in sales for the first quarter of launch along with positive launch metrics suggest a very promising roll-out of EXPAREL and expect the momentum to continue.”
As of August 3rd, Pacira stated that 428 customers have ordered EXPAREL which is up from 164 customers as of May 8th and that they are adding roughly 26 new customers per week, noted today’s report.
“49% of all accounts and 55% of hospital accounts have reordered with some accounts having ordered up to 15 times,” said Lau. “In our view, the reorder patterns suggest that initial physician experience has been positive and utilization will continue to grow as more hospitals gain access to EXPAREL”
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $14.94 yesterday, with a 52 week range of $6.51-$16.93.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Downgrades Thoratec (THOR) to Neutral
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
